| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mercedeh Farhat Sabet, Sumanta Barman, Mathias Beller, Sven G Meuth, Nico Melzer, Orhan Aktas, Norbert Goebels, Tim Prozorovsk. Myelinating Co-Culture as a Model to Study Anti-NMDAR Neurotoxicity. International journal of molecular sciences. vol 24. issue 1. 2023-01-08. PMID:36613687. |
anti-nmda receptor (nmdar) encephalitis is frequently associated with demyelinating disorders (e.g., multiple sclerosis (ms), neuromyelitis optica spectrum disorder (nmosd), myelin oligodendrocyte glycoprotein-associated disease (mogad)) with regard to clinical presentation, neuropathological and cerebrospinal fluid findings. |
2023-01-08 |
2023-08-14 |
Not clear |
| Jorge Guzmán, Francisco Vera, Bernardita Soler, Reinaldo Uribe-San-Martin, Lorena García, Adolfo Del-Canto, Andrea Schlatter, Mauricio Salazar, Fernando Molt, Karla Ramirez, José Marín, Carolina Pelayo, Juan Pablo Cruz, Sebastián Bravo-Grau, Claudia Cárcamo, Ethel Ciamp. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) in Chile: lessons learned from challenging cases. Multiple sclerosis and related disorders. vol 69. 2022-12-15. PMID:36521387. |
anti-myelin oligodendrocyte glycoprotein (mog) antibody associated disease (mogad) is an emerging disorder recognized as a clinical entity distinct from multiple sclerosis and aquaporin-4-positive neuromyelitis optica spectrum disorders (nmosd-aqp4+), and its phenotypic spectrum continues to expand. |
2022-12-15 |
2023-08-14 |
Not clear |
| Itay Lotan, Thibo Billiet, Annemie Ribbens, Wim Van Hecke, Benny Huang, Ilya Kister, Eyal Lota. Volumetric brain changes in MOGAD: A cross-sectional and longitudinal comparative analysis. Multiple sclerosis and related disorders. vol 69. 2022-12-13. PMID:36512956. |
relatively little is known about how global and regional brain volumes changes in myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) compare with multiple sclerosis (ms), neuromyelitis optica spectrum disorder (nmosd), and healthy controls (hc). |
2022-12-13 |
2023-08-14 |
Not clear |
| Hadas Stiebel-Kalish, Kerstin Rubarth, Karny Shouchane-Blum, Alon Tiosano, Itay Lotan, Mark A Hellmann, Adi Wilf-Yarkoni, Omer Bialer, Eoin P Flanagan, Sean J Pittock, M Tariq Bhatti, Tanja Schmitz-Hübsch, Paul Friedemann, Susanna Asseyer, John J Che. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis. Scientific reports. vol 12. issue 1. 2022-12-09. PMID:36494385. |
optic neuritis (on) is a frequent presentation at onset of multiple sclerosis (ms), neuromyelitis optica spectrum disorder (nmosd), and myelin oligodendrocyte glycoprotein antibody-associated disease (mogad). |
2022-12-09 |
2023-08-14 |
Not clear |
| Giulia Fadda, Eoin P Flanagan, Laura Cacciaguerra, Jiraporn Jitprapaikulsan, Paolo Solla, Pietro Zara, Elia Sech. Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. Frontiers in neurology. vol 13. 2022-11-24. PMID:36419536. |
three main demyelinating disorders of the central nervous system, namely multiple sclerosis (ms), aquaporin-4-igg-positive neuromyelitis optica spectrum disorders (aqp4+nmosd) and myelin oligodendrocyte glycoprotein-igg associated disease (mogad), can induce spinal cord inflammation through different pathogenic mechanisms, resulting in a more or less profound disruption of spinal cord integrity. |
2022-11-24 |
2023-08-14 |
Not clear |
| Neda Karami, Hadi Aligholi, Moosa Rahimi, Hassan Azari, Tahereh Kalantar. G Protein Coupled Receptors Potentially Involved in Oligodendrogenesis: A Gene Expression Analysis. Iranian journal of public health. vol 51. issue 10. 2022-11-23. PMID:36415811. |
multiple sclerosis (ms) is a chronic demyelinating disease of the central nervous system characterized by infiltration of inflammatory leukocytes to the cns followed by oligodendrocyte cell death, myelin sheath destruction, and axonal injury. |
2022-11-23 |
2023-08-14 |
Not clear |
| Dimitrios C Ladakis, Jennifer Gould, Jenny M Khazen, Julia M Lefelar, Scott Tarpey, Charles J Bies, Rebecca Salky, Kathryn C Fitzgerald, Pavan Bhargava, Bardia Nourbakhsh, Elias S Sotircho. Fatigue is a common symptom in myelin oligodendrocyte glycoprotein antibody disease. Multiple sclerosis journal - experimental, translational and clinical. vol 8. issue 4. 2022-11-21. PMID:36407471. |
unlike multiple sclerosis and neuromyelitis optica, the burden of fatigue in myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) is unclear. |
2022-11-21 |
2023-08-14 |
Not clear |
| Ali Jahanbazi Jahan-Abad, Hannah E Salapa, Cole D Libner, Patricia A Thibault, Michael C Levi. hnRNP A1 dysfunction in oligodendrocytes contributes to the pathogenesis of multiple sclerosis. Glia. 2022-11-16. PMID:36382566. |
oligodendrocyte (ol) damage and death are prominent features of multiple sclerosis (ms) pathology, yet mechanisms contributing to ol loss are incompletely understood. |
2022-11-16 |
2023-08-14 |
mouse |
| Adrian Budhram, Ario Mirian, Manas Sharm. Meningo-cortical manifestations of myelin oligodendrocyte glycoprotein antibody-associated disease: Review of a novel clinico-radiographic spectrum. Frontiers in neurology. vol 13. 2022-11-07. PMID:36341089. |
myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) is an inflammatory demyelinating disease that is distinct from multiple sclerosis. |
2022-11-07 |
2023-08-14 |
Not clear |
| Thomas Garton, Alexander J Gill, Peter A Calabres. Distinct mechanisms of oligodendrocyte injury inform therapeutic interventions in multiple sclerosis. Brain : a journal of neurology. 2022-11-03. PMID:36325693. |
distinct mechanisms of oligodendrocyte injury inform therapeutic interventions in multiple sclerosis. |
2022-11-03 |
2023-08-14 |
Not clear |
| Anna Zhou, Weihua Zhang, Changhong Ren, Ji Zhou, Haoxiao Chang, Xiaotun Re. High levels of cerebrospinal fluid soluble triggering receptor expressed on myeloid cells 2 might be a biomarker of activity in pediatric patients with MOG-AD. Frontiers in pediatrics. vol 10. 2022-10-31. PMID:36313865. |
myelin oligodendrocyte glycoprotein antibody disease (mog-ad) is characterized by its monophasic or relapsing course and inflammatory demyelinating condition which is unable to be classified in typical multiple sclerosis (ms) or other known neuroinflammatory conditions. |
2022-10-31 |
2023-08-14 |
Not clear |
| Maria-Eleftheria Evangelopoulos, Georgios Koutsis, Fotini Boufidou, Manolis Markiano. Cholesterol levels in plasma and cerebrospinal fluid in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Neurobiology of disease. 2022-10-09. PMID:36209949. |
it is unclear whether lack of remyelination in multiple sclerosis (ms) results from an insufficient capacity of oligodendrocyte precursor cells to differentiate or from cholesterol insufficiency. |
2022-10-09 |
2023-08-14 |
human |
| Itay Lotan, Shuhei Nishiyama, Giovanna S Manzano, Melissa Lydston, Michael Lev. COVID-19 and the risk of CNS demyelinating diseases: A systematic review. Frontiers in neurology. vol 13. 2022-10-07. PMID:36203986. |
viral infections are a proposed possible cause of inflammatory central nervous system (cns) demyelinating diseases, including multiple sclerosis (ms), neuromyelitis optica spectrum disorder (nmosd), and myelin oligodendrocyte glycoprotein antibody-associated disease (mogad). |
2022-10-07 |
2023-08-14 |
Not clear |
| Rosa Cortese, Ferran Prados Carrasco, Carmen Tur, Alessia Bianchi, Wallace Brownlee, Floriana De Angelis, Isabel De La Paz, Francesco Grussu, Lukas Haider, Anu Jacob, Baris Kanber, Lise Magnollay, Richard S Nicholas, Anand Trip, Marios Yiannakas, Ahmed T Toosy, Yael Hacohen, Frederik Barkhof, Olga Ciccarell. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging. Neurology. 2022-10-03. PMID:36192175. |
relapsing remitting multiple sclerosis (rrms), aquaporin4 antibody-positive neuromyelitis optica spectrum disorder (aqp4-nmosd) and myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) may have overlapping clinical features. |
2022-10-03 |
2023-08-14 |
Not clear |
| Tarun Kapoor, Sidharth Mehan, Manisha Suri, Nidhi Sharma, Nitish Kumar, Acharan S Narula, Abdulrahman Alshammari, Abdullah F Alasmari, Metab Alharbi, Mohammed A Assiri, Reni Kalfi. Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis. Cells. vol 11. issue 18. 2022-09-23. PMID:36139346. |
forskolin, an adenylcyclase/camp/creb signaling activator restoring myelin-associated oligodendrocyte destruction in experimental ethidium bromide model of multiple sclerosis. |
2022-09-23 |
2023-08-14 |
rat |
| Tarun Kapoor, Sidharth Mehan, Manisha Suri, Nidhi Sharma, Nitish Kumar, Acharan S Narula, Abdulrahman Alshammari, Abdullah F Alasmari, Metab Alharbi, Mohammed A Assiri, Reni Kalfi. Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis. Cells. vol 11. issue 18. 2022-09-23. PMID:36139346. |
multiple sclerosis (ms) is a chronic neurodegenerative disease marked by oligodendrocyte loss, which results in central neuronal demyelination. |
2022-09-23 |
2023-08-14 |
rat |
| Yizi Zhu, Mingzhu Chen, Yubo Zhang, Mei Ha. Stemazole Promotes Oligodendrocyte Precursor Cell Survival In Vitro and Remyelination In Vivo. International journal of molecular sciences. vol 23. issue 18. 2022-09-23. PMID:36142668. |
maintaining the normal function of oligodendrocyte precursor cells (opcs) and protecting opcs from damage is the basis of myelin regeneration in multiple sclerosis (ms). |
2022-09-23 |
2023-08-14 |
Not clear |
| Ünsal Yılmaz, Kıvılcım Gücüyener, Merve Yavuz, İbrahim Öncel, Mehmet Canpolat, Sema Saltık, Olcay Ünver, Ayşegül Neşe Çıtak Kurt, Ayşe Tosun, Sanem Yılmaz, Bilge Özgör, İlknur Erol, Ülkühan Öztoprak, Duygu Aykol Elitez, Meltem Çobanoğulları Direk, Muhittin Bodur, Serap Teber, Banu Anla. Re-examining the characteristics of pediatric multiple sclerosis in the era of antibody-associated demyelinating syndromes. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. vol 41. 2022-09-22. PMID:36137476. |
the discovery of anti-myelin oligodendrocyte glycoprotein (mog)-igg and anti-aquaporin 4 (aqp4)-igg and the observation on certain patients previously diagnosed with multiple sclerosis (ms) actually have an antibody-mediated disease mandated re-evaluation of pediatric ms series. |
2022-09-22 |
2023-08-14 |
Not clear |
| Iro Triantafyllakou, Nausicaa Clemente, Ravi Kumar Khetavat, Umberto Dianzani, Theodore Tselio. Development of PLGA Nanoparticles with a Glycosylated Myelin Oligodendrocyte Glycoprotein Epitope (MOG Molecular pharmaceutics. 2022-09-13. PMID:36098508. |
development of plga nanoparticles with a glycosylated myelin oligodendrocyte glycoprotein epitope (mog multiple sclerosis (ms) is one of the most common neurodegenerative diseases in young adults, with early clinical symptoms seen in the central nervous system (cns) myelin sheaths due to an attack caused by the patient's immune system. |
2022-09-13 |
2023-08-14 |
Not clear |
| Vanja Tepavčević, Catherine Lubetzk. Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier? Brain : a journal of neurology. 2022-09-12. PMID:36093726. |
oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier? |
2022-09-12 |
2023-08-14 |
Not clear |